State of the art of Smo antagonists for cancer therapy : advances in the target receptor and new ligand structures
Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 6 vom: 08. März, Seite 617-638 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Espinosa-Bustos, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.02.2020 Date Revised 04.02.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/fmc-2018-0497 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295350490 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295350490 | ||
| 003 | DE-627 | ||
| 005 | 20231225083454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0497 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM295350490 | ||
| 035 | |a (NLM)30912670 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Espinosa-Bustos, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a State of the art of Smo antagonists for cancer therapy |b advances in the target receptor and new ligand structures |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.02.2020 | ||
| 500 | |a Date Revised 04.02.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Since the Hedgehog signaling pathway has been associated with cancer, it has emerged as a therapeutic target for cancer therapy. The main target among the key Hedgehog proteins is the GPCR-like Smo receptor. Therefore, some Smo antagonists that have entered clinical trials, including the US FDA-approved drugs vismodegib and sonidegib, to treat basal cell carcinoma and medulloblastoma. However, early resistance of these drugs has spawned the need to understand the molecular bases of this phenomena. We therefore reviewed details about Smo receptor structures and the best Smo antagonist chemical structures. In addition, we discussed strategies that should be considered to develop new, safer generations of Smo antagonists that avoid current clinical limitations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Hedgehog signaling pathway | |
| 650 | 4 | |a Smo antagonists | |
| 650 | 4 | |a Smoothened receptor | |
| 650 | 4 | |a anticancer compounds | |
| 650 | 4 | |a cancer therapy | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Hedgehog Proteins |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a SMO protein, human |2 NLM | |
| 650 | 7 | |a Smoothened Receptor |2 NLM | |
| 700 | 1 | |a Mella, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Soto-Delgado, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Salas, Cristian O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d 2009 |g 11(2019), 6 vom: 08. März, Seite 617-638 |w (DE-627)NLM194822109 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:6 |g day:08 |g month:03 |g pages:617-638 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/fmc-2018-0497 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 6 |b 08 |c 03 |h 617-638 | ||